{
  "id": 4637239,
  "title": "Biotech Startup Investment Held Steady Even As AI Funding Surged",
  "url": "https://urgent.news/2026/08/31/biotech-startup-investment-held-steady-even-as-ai-funding-surged",
  "topic": "ai",
  "section": "AI",
  "published": "2026-08-31T11:00:52.000Z",
  "source": {
    "name": "Crunchbase News",
    "slug": "crunchbase-news",
    "url": "https://news.crunchbase.com/health-wellness-biotech/startup-investment-exits-steady-ai-2026/"
  },
  "original_language": "en",
  "account": "While the AI boom has disrupted funding patterns across the startup sector, biotech has remained a steady sector for investment. For the past few years, global funding to biotech startups has consistently hovered between $36 billion and $40 billion. Despite an overall record level of venture investment in the first half of this year, biotechs secured a respectable share of the remaining funds.\n\nA few biotechs picked up large financings. AI-focused biotechs garnered over $6 billion this year, with large rounds including Isomorphic Labs' $2.1 billion Series B, Earendil Labs' $787 million, and Chai Discovery's $400 million. Other notable AI-focused fundraisers include NewLimit, a longevity startup, which raised $435 million.\n\nWhile many heavily funded biotechs are at later stages, the overall startup pipeline remains early-stage, with more than half of investment going to seed and early-stage rounds. Some biotechs have gone public early, such as Kailera Therapeutics, Kardigan, and Latigo Biotherapeutics.\n\nLater-stage biotechs also participated in IPOs, including Parabilis Medicines, a cancer therapeutics company. Biotech startups delivered significant M&A exits as well, with 12 transactions valued at $1 billion or more. Overall, biotech funding and exits remain healthy, even though conditions appear tame compared to the AI investment exuberance.",
  "summary": "While the AI boom has disrupted funding patterns across the startup sphere, biotech has remained a rare steady sector for investment. For the past few years, global funding to biotech startups has hovered between $36 billion and $40 billion. Per Crunchbase data, 2026 is on track to stay close to that range.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}